RUSH2A

Clinical Trial

NCT03146078 Active, Not recruiting

RUSH2A

Rate of Progression in USH2A Related Retinal Degeneration

Observational

Disease

Disease type

Hereditary retinal disease

Paediatric clinical trials

Retinitis Pigmentosa

Usher Syndrome

Orphan drug recognition

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

11/08/2017

Closing date

28/04/2023

Inclusion criteria :

Exclusion criteria :

Funding

patient organisation

Members involved

Main investigators

Dr Katarina Stingl

Representative

Germany

Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Others investigators

Pr Bart LEROY

Representative

Belgium

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Elfride DE BAERE

Substitute

Belgium

Genetic Diagnostics (TWG6), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)